Finch Therapeutics Group, Inc.

FNCHCIK 0001733257 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 26, 2024. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0033

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

Oct 21, 2024no items parsed Aug 12, 2024no items parsed May 24, 2024no items parsed May 17, 2024no items parsed Apr 3, 2024no items parsed

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Finch Therapeutics Group, Inc.

Name	Roles	Filings
Perry Gregory D	Officer	1
Viney Joanne L.	Director	1

Showing 11-12 of 12

Per pagePrevPage 3 of 3

Top performers

Insiders ranked by realized 90-day signed return on their open-market trades at Finch Therapeutics Group, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.

#	Insider	Trades	Win rate	Avg	Median	Best	Worst
1	Smisek Jeffery A	3	100%	+42.9%	+48.1%	+48.1%	+32.4%

All filings

26 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 9, 2023	Blischak Matthew P. Chief Executive Officer	Holdings only	-	-	-

Filed		Top transaction	Shares	Price	Value